Literature DB >> 30950234

Evaluation of endoscopic reintervention for self-expandable metallic stent obstruction after stent-in-stent placement for malignant hilar biliary obstruction.

Mitsuru Okuno1, Tsuyoshi Mukai1, Takuji Iwashita2, Hironao Ichikawa1, Yuhei Iwasa1, Naoki Mita2, Kensaku Yoshida2, Keisuke Iwata3, Eiichi Tomita1, Masahito Shimizu2.   

Abstract

BACKGROUND: Bilateral self-expandable metallic stent (SEMS) placement is effective for long-term management of unresectable malignant hilar biliary obstruction (UMHBO). However, endoscopic reintervention (ERI) for bilateral SEMSs is not well-studied. This study aimed to evaluate ERI efficacy after stent-in-stent placement.
METHODS: Data of 31 patients who underwent ERI from May 2000 to July 2018 were analyzed.
RESULTS: The technical success rate was 80.7% (25/31) and no adverse events occurred. The functional success rate was 100% (25/25). In a multivariate logistic regression analysis, the angle between the bilateral SEMSs (ABBS) >104° (odds ratio 50.49, 95% CI 3.370-2131, P = 0.0039) and overgrowth (odds ratio 25.70, 95% CI 1.121-1234, P = 0.0423) were risk factors for ERI failure. Multiple liver metastases, which sometimes cause overgrowth, were also risk factors. After ERI, some patients underwent additional SEMS (n = 4), plastic stent (n = 14) placement, or internal cleaning of the initial SEMS alone (n = 7). There were no significant intergroup differences in the 50% time to recurrent biliary obstruction.
CONCLUSIONS: ABBS >104° and overgrowth were risk factors for ERI failure after stent-in-stent placement. In the decision-making process for initial SEMS placement for UMHBO, patient condition should be considered, including the angle between bilateral bile ducts and multiple liver metastases.
© 2019 Japanese Society of Hepato-Biliary-Pancreatic Surgery.

Entities:  

Keywords:  Angle between bilateral self-expandable metallic stent; Endoscopic reintervention; Malignant hilar biliary obstruction; Recurrent biliary obstruction; Stent-in-stent placement

Mesh:

Year:  2019        PMID: 30950234     DOI: 10.1002/jhbp.626

Source DB:  PubMed          Journal:  J Hepatobiliary Pancreat Sci        ISSN: 1868-6974            Impact factor:   7.027


  5 in total

1.  Endoscopic bilateral revision after metal stent deployment for hepatic hilar obstruction using molting technique (with videos).

Authors:  Masahiro Yamamura; Takeshi Ogura; Saori Ueno; Atsushi Okuda; Nobu Nishioka; Masanori Yamada; Kazuya Ueshima; Jun Matsuno; Yoshitaro Yamamoto; Kazuhide Higuchi
Journal:  Therap Adv Gastroenterol       Date:  2022-04-29       Impact factor: 4.802

Review 2.  Recent advances regarding endoscopic biliary drainage for unresectable malignant hilar biliary obstruction.

Authors:  Hironari Kato; Kazuyuki Matsumoto; Hiroyuki Okada
Journal:  DEN open       Date:  2021-09-07

3.  Novel J-tip guidewire for reintervention after stent-by-stent placement in patients with malignant hilar biliary obstruction.

Authors:  Tadahisa Inoue; Mayu Ibusuki; Rena Kitano; Kazumasa Sakamoto; Satoshi Kimoto; Yuji Kobayashi; Yoshio Sumida; Yukiomi Nakade; Kiyoaki Ito; Masashi Yoneda
Journal:  Endosc Int Open       Date:  2022-09-14

4.  Brachytherapy Drainage Catheter and Chemotherapy for Unresectable Pancreatic Carcinoma Combined with Obstructive Jaundice.

Authors:  Dechao Jiao; Kaihao Xu; Gauri Mukhiya; Yiming Liu; Kunpeng Wu; Zongming Li; Jianzhuang Ren; Xinwei Han
Journal:  Front Oncol       Date:  2022-07-14       Impact factor: 5.738

5.  Endoscopic retrograde cholangiopancreatography drainage for palliation of malignant hilar biliary obstruction - stent-in-stent or side-by-side? A systematic review and meta-analysis.

Authors:  Gabriel Mayo Vieira de Souza; Igor Braga Ribeiro; Mateus Pereira Funari; Diogo Turiani Hourneaux de Moura; Maria Vitória Cury Vieira Scatimburgo; João Remí de Freitas Júnior; Sergio A Sánchez-Luna; Renato Baracat; Eduardo Turiani Hourneaux de Moura; Wanderley Marques Bernardo; Eduardo Guimarães Hourneaux de Moura
Journal:  World J Hepatol       Date:  2021-05-27
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.